1. Felig P. The glucose-alanine cycle. Metabolism 1973;22:179–207.
2. Daxboeck F, Gattringer R, Mustafa S, Bauer C, Assadian O. Elevated serum alanine aminotransferase (ALT) levels in patients with serologically verified Mycoplasma pneumoniae pneumonia. Clin Microbiol Infect 2005;11:507–510.
5. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC, Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47:1363–1370.
7. Nyblom H, Bjornsson E, Simren M, Aldenborg F, Almer S, Olsson R. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 2006;26:840–845.
9. Glinghammar B, Rafter I, Lindstrom AK, et al. Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues and plasma. Int J Mol Med 2009;23:621–631.
11. Stankewicz MJ, Cheng S, Martinez-Carrion M. Mitochondrial glutamate aspartate transaminase. Differential action of thiol reagents with the supernatant enzyme. Biochemistry 1971;10:2877–2884.
12. Watanabe T, Wada H. Comparative studies on the primary structure of soluble and mitochondrial glutamic oxaloacetic transaminase isozymes. I. Similar peptides isolated by cyanogen bromide cleavage. Biochem Biophys Res Commun 1971;43:1310–1317.
15. Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013;57:1651–1653.
16. Burroughs AK, Thalheimer U. Hepatic venous pressure gradient in 2010: optimal measurement is key. Hepatology 2010;51:1894–1896.
18. Desmet VJ, Knodell RG, Ishak KG, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435]. J Hepatol 2003;38:382–386.
19. Asselah T, Marcellin P, Bedossa P. Improving performance of liver biopsy in fibrosis assessment. J Hepatol 2014;61:193–195.
20. Klingenberg B, Agresti A. Multivariate extensions of Mc-Nemar's test. Biometrics 2006;62:921–928.
21. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254–2261.
22. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481–488.
23. Kim MY, Baik SK, Yea CJ, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol 2009;21:1241–1246.
24. Kumar M, Kumar A, Hissar S, et al. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus. Liver Int 2008;28:690–698.
26. Suk KT, Kim HC, Namkung S, et al. Diagnostic accuracy of hepatic venous pressure gradient measurement in the prediction of stage 1 compensated liver cirrhosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2013;25:1170–1176.
27. Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2010;31:1095–1103.
28. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007;381:107–113.
29. Cowan ML, Rahman TM, Krishna S. Proteomic approaches in the search for biomarkers of liver fibrosis. Trends Mol Med 2010;16:171–183.
30. Paradis V. Glycomics: a new taste of cirrhosis marker. J Hepatol 2005;43:913–914.
31. Baranova A, Liotta L, Petricoin E, Younossi ZM. The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis 2007;11:209–220.